Hsbc Holdings PLC Vir Biotechnology, Inc. Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$7.63 - $12.66 $210,626 - $349,479	27,605 Added 148.28%	46,222 $411,000
Q1 2024 May 15, 2024	SELL	$8.6 - $11.9 $26,737 - $36,997	-3,109 Reduced 14.31%	18,617 $188,000
Q4 2023 Feb 12, 2024	BUY	$7.76 - $10.29 $43,882 - $58,189	5,655 Added 35.19%	21,726 $218,000
Q3 2023 Nov 13, 2023	BUY	$9.14 - $24.62 $146,888 - $395,668	16,071 New	16,071 $150,000
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $49,228 - $83,845	-2,696 Reduced 16.37%	13,776 $270,000
Q2 2022 Aug 11, 2022	BUY	$19.08 - $26.7 $314,285 - $439,802	16,472 New	16,472 $422,000
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $182,954 - $345,446	-8,634 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$30.97 - $54.03 $267,394 - $466,495	8,634 New	8,634 $361,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.